Compare CNDT & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CNDT | SLGL |
|---|---|---|
| Founded | 2016 | 1997 |
| Country | United States | Israel |
| Employees | 51000 | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 232.4M | 247.1M |
| IPO Year | 2016 | 2016 |
| Metric | CNDT | SLGL |
|---|---|---|
| Price | $1.71 | $77.53 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $110.00 |
| AVG Volume (30 Days) | ★ 1.2M | 51.4K |
| Earning Date | 04-29-2026 | 05-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,042,000,000.00 | N/A |
| Revenue This Year | $2.01 | N/A |
| Revenue Next Year | $4.06 | $223.84 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.15 | $0.62 |
| 52 Week High | $2.98 | $97.97 |
| Indicator | CNDT | SLGL |
|---|---|---|
| Relative Strength Index (RSI) | 66.15 | 50.60 |
| Support Level | $1.16 | $71.01 |
| Resistance Level | $2.10 | $84.75 |
| Average True Range (ATR) | 0.10 | 5.40 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 73.20 | 47.96 |
Conduent Inc acts as a provider of business process services with expertise in transaction-intensive processing, analytics, and automation. The company provides industry-focused service offerings in growth markets such as Healthcare and Transportation as well as provides multi-industry services such as transaction processing, customer care, and payment services. It operates through three segments namely Commercial Industries which is the key revenue-driving segment, Government Services, and Transportation. The group operates its business in the United States, Europe, and Other areas of which the majority of revenue is generated in the United States.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.